
Salt AI provides a development platform for life sciences organizations to adopt and harness AI faster. Their platform focuses on reliable and reproducible AI workflows, engineered to accommodate advancements in computational techniques for drug discovery. Salt AI offers a step-change in speed and efficiency, with models optimized for faster output and reduced compute costs. The platform emphasizes transparency and collaboration, allowing stakeholders beyond computational biologists to engage in shaping workflows. A key client, the Ellison Medical Institute, experienced a 22x increase in drug candidate evaluation speed and an 85% reduction in technical implementation time, leading to faster innovation in cancer therapeutics.

Salt AI provides a development platform for life sciences organizations to adopt and harness AI faster. Their platform focuses on reliable and reproducible AI workflows, engineered to accommodate advancements in computational techniques for drug discovery. Salt AI offers a step-change in speed and efficiency, with models optimized for faster output and reduced compute costs. The platform emphasizes transparency and collaboration, allowing stakeholders beyond computational biologists to engage in shaping workflows. A key client, the Ellison Medical Institute, experienced a 22x increase in drug candidate evaluation speed and an 85% reduction in technical implementation time, leading to faster innovation in cancer therapeutics.
Focus: Visual, enterprise-grade AI workflow platform for life sciences and healthcare
Founding year: 2023
Headquarters: Los Angeles, CA
Seed funding: $3M (seed)
Notable partnership: Ellison Medical Institute (research partnership)
Life sciences and healthcare AI workflows (protein design, biomarker discovery, drug discovery pipelines).
2023
Technology, Information and Internet
$3,000,000
Seed round reported in company announcement.
“Morpheus Ventures led seed; additional investors reported include Struck Capital and Irregular Expressions”
| Company |
|---|